UK Markets close in 8 hrs 4 mins

Adocia SA (0QAI.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
9.85+0.02 (+0.20%)
As of 06:28PM GMT. Market open.
Full screen
Previous close9.83
Bid0.00 x 0
Ask0.00 x 0
Day's range9.72 - 9.85
52-week range9.72 - 9.85
Avg. volumeN/A
Market cap68.737M
Beta (5Y monthly)1.00
PE ratio (TTM)N/A
EPS (TTM)-3.35
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Number of Shares and Voting Rights of ADOCIA as of October 31st, 2021

    LYON, France, November 19, 2021--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with inno

  • Business Wire

    Adocia Announces 2021 Third Quarter Financial Results and a Financing of €7 Million

    LYON, France, October 26, 2021--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today its third quarter financial results as well as the completion, today, of a financing of EUR 7 million.

  • Globe Newswire

    Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

    This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to AdociaBC Lispro addresses the Chinese prandial insulin market which is approx. $1.4bn today with double-digit growth LYON, France, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatments and other metab